Category: Health

Categories
Health

Well being-care shares are making a comeback, Jim Cramer says

Health-care stocks are making a comeback, Jim Cramer says

CNBC’s Jim Cramer on Thursday highlighted healthcare stocks, a rebounding segment he believes will help lead the market higher.

Health stocks are recovering after being discounted and “left for dead” due to the coronavirus pandemic, he said.

“I think the lagging health stocks are now being brought back to life at the expense of cyclical growth games and you should grab one before they all really take off,” said the Mad Money host.

The comments come after strong economic data helped the Dow Jones Industrial Average topped 34,000 for the first time in Thursday’s session. The 30-share index rose 305 points, or 0.9%, to close at 34,035.99, led by a rise in UnitedHealth Group shares.

UnitedHealth, an insurer and a Dow component, released a quarterly report that beat analysts’ estimates. Positive action could also be seen at GlaxoSmithKline, Eli Lilly, Regeneron Pharmaceuticals and Johnson & Johnson, which have been hampered by the introduction of the Covid-19 vaccine, Cramer said.

With the exception of Johnson & Johnson, each of these stocks has risen double-digit from their recent lows to the start of the year.

“This cohort had fallen so out of favor that it ended up being of tremendous value. It was just waiting for the signal to move … [and] it happened, “said Cramer.” In view of the monumentality of this step, it is certainly far from over. “

Disclosure: Cramer’s charitable foundation owns shares in Eli Lilly.

Disclaimer of liability

Questions for Cramer?
Call Cramer at 1-800-743-CNBC

Would you like to dive deep into Cramer’s world? Open it up!
Mad Money Twitter – Jim Cramer Twitter – Facebook – Instagram

Questions, comments, suggestions for the Mad Money website? madcap@cnbc.com

Categories
Health

States Wrestle With Vaccine Pause as Federal Officers Reassure Public

States Struggle With Vaccine Pause as Federal Officials Reassure Public

Dr. Anthony S. Fauci sagte am Donnerstag, er hoffe, dass die Nation bald wieder in der Lage sein werde, den Johnson & Johnson-Impfstoff zu verwenden, als eine „Pause“, die nun auf unbestimmte Zeit droht, die Impfbemühungen in Übersee und in einigen der am stärksten ausgegrenzten Länder anzukurbeln Gemeinden in den Vereinigten Staaten.

Dr. Fauci, Präsident Bidens oberster medizinischer Berater für die Pandemie, äußerte sich während einer Anhörung des House Select-Unterausschusses zur Coronavirus-Krise, in der er und andere hochrangige Gesundheitsbehörden des Bundes die Amerikaner anflehten, sich weiterhin impfen zu lassen, und versuchten, die Nation zu beruhigen dass alle drei staatlich zugelassenen Impfstoffe sicher sind.

“Hoffentlich werden wir bald eine Entscheidung treffen, ob wir mit diesem sehr wirksamen Impfstoff wieder auf Kurs kommen können oder nicht”, sagte Dr. Fauci dem Gremium. Angesichts der zunehmenden Fälle im Mittleren Westen, fügte er hinzu, befindet sich die Nation in einer „prekären Situation“, und es ist unbedingt erforderlich, „so viele Menschen so schnell und so schnell wie möglich zu impfen“.

Es wurde jedoch zunehmend klarer, dass eine Suspendierung, die ursprünglich zwei bis drei Tage dauern sollte, erheblich länger dauern würde, da die Beamten mit Berichten über mindestens sechs seltene Fälle von Blutgerinnung bei Frauen rangen, die mit dem Schuss von Johnson & Johnson immunisiert worden waren. Die Gesundheitsbehörden des Bundes versuchen zu entscheiden, ob sie den Ärzten empfehlen sollen, den Impfstoff wieder aufzunehmen, möglicherweise mit neuen Einschränkungen.

Der Impfstoff war kein wesentlicher Bestandteil der Impfkampagne der Biden-Regierung. Ungefähr 7,7 Millionen Amerikaner haben den Schuss von Johnson & Johnson erhalten, was weniger als 4 Prozent der mehr als 198 Millionen Dosen entspricht, die im ganzen Land verabreicht werden.

Obwohl diese Zahlen gering sind, sind viele der Menschen, gegen die der Impfstoff gerichtet ist, gefährdet: Obdachlose in Baltimore, Bewohner des District of Columbia, Arme und Nichtversicherte in Massachusetts, Landbewohner in einer Reihe von Bundesstaaten. Alle Populationen sind mit einer Einzeldosis leichter zu erreichen als das Zwei-Dosis-Regime der Impfstoffe Pfizer und Moderna.

Etwa 10 Millionen Dosen, die in die Staaten verschifft werden, stehen jetzt in den Regalen und warten auf eine Entscheidung. Und viele Menschen, die möglicherweise keinen Schuss suchen, aber mit mobilen Kliniken und einer konzertierten Kontaktaufnahme hätten erreicht werden können, könnten zumindest vorerst zurückgelassen werden.

„Alle unsere Impfstoffe, Anbieter im ganzen Bundesstaat und unser Team im Gesundheitsministerium von Minnesota arbeiten intensiv daran, die Dinge zu planen und zu verschieben. Es handelt sich offensichtlich um eine Reihe von Dominosteinen “, sagte Jan Malcolm, Minnesotas Gesundheitskommissar. “Wir bedauern sehr die Kliniken, die wegen der Pause bei J & J kurzfristig abgesagt werden mussten, und das wird auch in den kommenden Wochen ein Problem sein.”

Der Pressesprecher des Weißen Hauses, Jen Psaki, kalibrierte erneut das Versprechen von Präsident Biden, bis Ende Mai genügend Impfstoffe für alle amerikanischen Erwachsenen zu beschaffen. Jetzt betont das Weiße Haus, dass alle Erwachsenen, die einen Impfstoff wollen, einen bekommen werden.

“Das bedeutet, dass bis Ende Mai für etwa 80 Prozent der Bevölkerung, bis Ende Juli etwa 90 Prozent der Bevölkerung”, sagte Frau Psaki gegenüber Reportern.

In Lexington, Kentucky, wurde eine Johnson & Johnson-Klinik für Freitag abgesagt, sodass rund 400 Personen ohne Termin waren. Allen wurde eine Last-Minute-Option angeboten, um einen Moderna-Impfstoff zu erhalten, aber nur etwa 65 nahmen das Angebot an, sagte Kevin Hall, ein Sprecher des Gesundheitsministeriums von Lexington-Fayette County.

“Dies war ein großer Erfolg für unsere Planung”, sagte Hall, dessen Agentur den Johnson & Johnson-Impfstoff bereits für Insassen und Obdachlose verwendet hatte und geplant hatte, in den kommenden Wochen Nachbarschaftskliniken anzubieten. “Die Logistik für den Abzug einer Klinik für die erste und zweite Dosis wird sehr viel schwieriger.”

Dr. Letitia Dzirasa, die Gesundheitskommissarin in Baltimore, sagte, die Stadt habe bisher nur etwa 1.400 Dosen des Johnson & Johnson-Impfstoffs erhalten, aber viele seien auf obdachlose Bewohner ausgerichtet. Die Stadt muss möglicherweise ihre Pläne für Pop-up-Kliniken im Freien überdenken und sich bemühen, die Bewohner des Heimatlandes diesen Sommer mit dem Impfstoff mit einer Dosis zu erreichen, sagte sie.

“Wir dachten, J & J wäre der ideale Kandidat, um diese Arbeit zu unterstützen”, sagte sie.

In Washington, DC, verzögern Beamte ein Programm, um mit Johnson & Johnson-Schüssen heimatgebundene Bewohner zu erreichen. Die Stadt hat diese Woche Termine für etwa 1.200 Personen abgesagt, aber inzwischen sollten alle eine Einladung zu einem neuen Termin für einen der beiden anderen von der Bundesregierung zugelassenen Impfstoffe erhalten haben, die von Pfizer-BioNTech und Moderna entwickelt wurden.

Andere staatliche und lokale Gesundheitsbehörden sagten, sie würden mit diesen beiden Impfstoffen auskommen. In der Region Flint, Michigan, die einige der höchsten Fallraten des Landes in jüngster Zeit aufweist, gaben Beamte an, dass sie alle geplanten Kliniken auch ohne den Impfstoff von Johnson & Johnson abdecken konnten.

“Bisher war es reibungslos”, sagte Dr. Pamela Hackert, die medizinische Gesundheitsbeauftragte des Gesundheitsministeriums von Genesee County, in einer E-Mail.

Aktualisiert

15. April 2021, 16:49 Uhr ET

Am Des Moines Area Community College in Iowa konnten Administratoren diesen Monat drei Kliniken auf dem Campus einrichten, in denen die Studenten einen Impfstoff mit zwei Dosen erhalten können. Rob Denson, der College-Präsident, sagte, er sei erfreut und überrascht über seine Fähigkeit, diese zukünftigen Kliniken so schnell zu organisieren.

“Ich denke, wir werden in relativ kurzer Zeit mit Impfstoffen überflutet sein”, sagte er.

Eine längere Unterbrechung der Verfügbarkeit von Johnson & Johnson wird sich jedoch allmählich verschlechtern, insbesondere in ärmeren Staaten mit schwer erreichbaren Bevölkerungsgruppen. Eine Sprecherin von Dr. José Romero, dem Gesundheitsminister in Arkansas, sagte: „Die Pause sollte ausreichend lang sein, um Sicherheitsfragen zu beantworten, aber nicht länger als nötig verlängert werden.

“Seine Sorge ist, dass eine überlange Pause das Zögern erhöht und das Vertrauen verringert”, sagte die Sprecherin Danyelle McNeill. Dr. Romero leitet das Beratungsgremium zu den Zentren für die Kontrolle und Prävention von Krankheiten, die letztendlich empfehlen werden, wie mit dem Johnson & Johnson-Impfstoff verfahren werden soll.

Die Suspendierung in den Vereinigten Staaten kann tiefgreifendere Konsequenzen in Übersee haben, wo bisher nur ein Bruchteil der übrigen Welt geimpft wurde. Dr. Luciana Borio, eine ehemalige amtierende Chefwissenschaftlerin der Food and Drug Administration, die auch im Nationalen Sicherheitsrat des Weißen Hauses von Trump tätig war, sagte, der Impfstoff von Johnson & Johnson sei ein entscheidendes Instrument, um die Ausbreitung des Virus auf der ganzen Welt zu stoppen .

“Es ist ein Impfstoff, der schnell in sehr großem Maßstab hergestellt werden kann und viel einfachere Verteilungsverfahren hat”, sagte sie. “Die Welt braucht mehr Unternehmen wie J & J, die ihren Impfstoff liefern.”

Die Beamten zählten sowohl auf Johnson & Johnson als auch auf einen anderen leicht zu verteilenden Impfstoff von AstraZeneca, um Impfungen in schwer zugängliche Teile der Welt zu bringen. Jüngste Berichte über seltene Blutgerinnsel bei Empfängern des AstraZeneca-Impfstoffs haben jedoch eine Reihe von Nationen dazu veranlasst, seine Verwendung zu überdenken.

Einige Regionen beschlossen, zu Johnson & Johnson zu wechseln. Vor zwei Wochen hat die Afrikanische Union 400 Millionen Dosen erhalten, obwohl sich wohlhabendere Nationen gescheut haben. Die Europäische Union sagte, sie werde nicht mehr von Johnson & Johnson kaufen, und Australien kündigte an, keine Dosen zu kaufen.

In den Vereinigten Staaten schlugen Mitglieder des CDC-Beratungsgremiums am Mittwoch vor, dass es eine Woche bis 10 Tage dauern würde, bis sie über genügend Informationen verfügen, um die Risiken des Impfstoffs zu bewerten und eine Entscheidung über seine Zukunft in den Vereinigten Staaten zu treffen. Dr. Fauci und zwei weitere Beamte – Dr. Rochelle Walensky, der CDC-Direktor, und Dr. David Kessler, der die Impfbemühungen der Biden-Regierung leitet – forderten die Amerikaner auf, sich weiterhin impfen zu lassen.

“Ich hoffe, wir können alle zusammenkommen und diese Botschaft senden”, sagte Dr. Kessler, insbesondere angesichts der Verbreitung besorgniserregender Varianten, und fügte hinzu, dass die drei vom Bund zugelassenen Impfstoffe “ein ausgezeichnetes Sicherheitsprofil” haben.

Was Sie über die Johnson & Johnson Vaccine Pause in den USA wissen müssen

    • Am 13. April 2021 forderten die US-Gesundheitsbehörden eine sofortige Unterbrechung der Verwendung des Einzeldosis-Impfstoffs Covid-19 von Johnson & Johnson, nachdem sechs Empfänger in den USA innerhalb von ein bis drei Wochen nach der Impfung eine seltene Erkrankung mit Blutgerinnseln entwickelt hatten.
    • Alle 50 Bundesstaaten, Washington, DC und Puerto Rico, haben die Verwendung des Impfstoffs vorübergehend eingestellt oder von empfohlenen Anbietern unterbrochen. Das US-Militär, staatlich geführte Impfstellen und eine Vielzahl privater Unternehmen, darunter CVS, Walgreens, Rite Aid, Walmart und Publix, pausierten die Injektionen ebenfalls.
    • Derzeit werden weniger als eine von einer Million Johnson & Johnson-Impfungen untersucht. Wenn tatsächlich ein Risiko für Blutgerinnsel durch den Impfstoff besteht – das noch ermittelt werden muss -, ist dieses Risiko äußerst gering. Das Risiko, in den USA an Covid-19 zu erkranken, ist weitaus höher.
    • Die Pause könnte die Impfbemühungen des Landes in einer Zeit erschweren, in der viele Staaten in neuen Fällen mit einem Anstieg konfrontiert sind und versuchen, das Zögern des Impfstoffs anzugehen.
    • Johnson & Johnson hat auch beschlossen, die Einführung seines Impfstoffs in Europa zu verzögern, da Bedenken hinsichtlich seltener Blutgerinnsel bestehen, was dem Impfschub in Europa einen weiteren Schlag versetzt. Südafrika, das von einer dort auftretenden ansteckenden Virusvariante am Boden zerstört wurde, stellte die Verwendung des Impfstoffs ebenfalls ein. Australien kündigte an, keine Dosen zu kaufen.

Die Berichte über Blutgerinnsel waren der zweite Schlag gegen den Johnson & Johnson-Impfstoff. Anfang dieses Monats hat eine Verwechslung von Inhaltsstoffen in einer Produktionsstätte in Baltimore, die Emergent BioSolutions gehört, bis zu 15 Millionen Dosen des Impfstoffs ruiniert. Die FDA inspiziert nun die Anlage, um festzustellen, ob dort hergestellte Dosen der Öffentlichkeit zugänglich gemacht werden können.

Während einer mehr als zweistündigen Anhörung fragte jedoch nur ein Gesetzgeber – der Vertreter Mark E. Green, Republikaner von Tennessee, der Arzt ist – nach dem Impfstoff von Johnson & Johnson. Er forderte die Ärzte auf, vorsichtig zu sein, wenn sie über die Ermittlungen sprachen, und sagte, er befürchte, dass sie Ängste schüren würden, die die Menschen davon abhalten würden, sich impfen zu lassen.

Und es gibt frühe Beweise dafür, dass die Besorgnis gut aufgenommen wird. Eine am Donnerstag vom Boston Children’s Hospital veröffentlichte Umfrage unter Survey Monkey ergab, dass die Bereitschaft, den Schuss von Johnson & Johnson zu erhalten, bei Amerikanern, die sich impfen lassen wollten, innerhalb von zwei Tagen um 26 Prozentpunkte zurückging. Laut der Umfrage, einem Projekt der Outbreaks Near Me-Initiative des Krankenhauses, einem Crowdsourcing-System zur Überwachung von Infektionskrankheiten, betrug der Rückgang bei Frauen, die sich impfen lassen wollten, 31 Prozentpunkte.

“Jedes Mal, wenn auf Bundesebene Bedenken oder rote Fahnen gehisst werden, wird dies die breite Öffentlichkeit beunruhigen”, sagte Dr. Dzirasa.

Die Sitzung am Donnerstag hatte den Untertitel „Ein wissenschaftlich fundierter Ansatz zur schnellen und sicheren Beendigung der Pandemie“. Aber was auch immer über Wissenschaft diskutiert wurde, wurde von parteipolitischer Haltung und Streit überschattet.

Demokraten machten sich Sorgen um den Fox News-Moderator Tucker Carlson, der seine Show genutzt hat, um fälschlicherweise zu behaupten, dass die Impfstoffe nicht funktionieren.

Die Republikaner, die gerade erst an der Südgrenze des Landes waren, nutzten die Sitzung, um den Umgang der Biden-Regierung mit der Einwanderungskrise anzugreifen. Sie winkten mit Fotos von Migranten, die unter beengten Verhältnissen lebten, und beschwerten sich über Testregeln für diejenigen, die in das Land einreisen.

Der Vertreter Jim Jordan, Republikaner von Ohio, und Dr. Fauci wiederholten ihren hitzigen Zusammenstoß, als Dr. Fauci das letzte Mal vor dem Panel im Juli aussagte.

“Sie schimpfen wieder”, sagte Dr. Fauci an einer Stelle.

“Ich schimpfe nicht”, antwortete Herr Jordan.

“Ja, das sind Sie”, beharrte Dr. Fauci.

Die Repräsentantin Maxine Waters, Demokratin von Kalifornien, deren Schwester an Covid-19 gestorben ist, sagte zu Dr. Fauci: „Ich liebe dich“ und sagte zu Herrn Jordan: „Halt den Mund.“

Noah Weiland, Rebecca Robbins und Sharon LaFraniere trugen zur Berichterstattung bei.

Categories
Health

Airline executives solid doubt with borders nonetheless closed

Airline executives cast doubt with borders still closed

An Airbus A330neo or A330-900 from Delta Air Lines with Neo engine option from the European aircraft manufacturer, as seen on the final approach at Amsterdam Schiphol AMS EHAM after a long-haul transatlantic flight.

Nicolas Economou | NurPhoto | Getty Images

Are you hoping to have a European vacation this summer? You may be out of luck.

In much of Europe, the borders for most US citizens have been closed for more than a year because of the coronavirus pandemic, and vice versa. Airline executives said Thursday they didn’t expect it to open in time for midsummer time.

Travel industry leaders have urged the Biden government on a plan to reopen the borders, including standards for health documentation such as evidence of a Covid-19 vaccine.

Ed Bastian, Delta Air Lines CEO, said on a quarterly call that the company is focused on lifting restrictions that have hampered travel between the US and the UK but other popular destinations may take longer.

The White House did not respond immediately.

The UK eased its lockdown restrictions this week, allowing pubs, hairdressers and retail stores to reopen. France and Italy reintroduced temporary bans last month to contain new Covid-19 infections, and vaccine distribution across Europe has been slow.

“When you think of other parts of Europe, there may be occasional markets opening this summer based on leisure traffic in the southern Mediterranean that people will be interested in,” Bastian said on the conference call. “But I don’t think continental Europe will open in any meaningful way until later in the year. We’re likely to miss out on much of the summer for most of continental Europe, unfortunately.”

Delta and competitors like American Airlines and United Airlines have stated that domestic travel has bounced back strongly from the depths of the pandemic, but international travel, which is still facing a web of entry restrictions and a delay in vaccinations, remains weak.

Delta announced Thursday that domestic passenger revenue in the first quarter was 66% lower than the same period in 2019 to $ 2.3 billion. However, transatlantic sales were 87% lower at $ 142 million, while trans-Pacific sales were down 89% at $ 62 million.

Naples, Italy versus Naples, Florida

American airlines have geared their once sprawling global networks towards domestic destinations, particularly those that offer outdoor attractions like beaches and mountains. The airlines have expanded tourist hotspots in Florida, Wyoming, and Montana. You’ve also seen a surge in demand for beach destinations in the Caribbean and Mexico.

American Airlines announced on Wednesday, for example, that it would bring its domestic flight schedule for the summer to almost the level of 2019.

Brian Znotins, vice president of network planning for American Airlines, told CNBC that even if the borders open in the coming season, demand for European summer vacation will be hard to generate.

“Usually a European vacation is planned months in advance,” he said. “If people want to go on a getaway this summer today, which many people are, they don’t feel very sure about booking a trip to Rome, so they’re going to make that hotel reservation in Jackson Hole or Honolulu or Cancun.

“You don’t expect demand to show up until the day after a country opens, especially from a leisure perspective,” he said.

Categories
Health

Biden Takes On Sagging Security Web With Plan to Repair Lengthy-Time period Care

Biden Takes On Sagging Safety Net With Plan to Fix Long-Term Care

President Biden’s $ 400 billion proposal to improve long-term care for older adults and people with disabilities was received either as a long overdue addition to the social security net or as an example of a misguided government transgression.

Republicans ridiculed the inclusion of elderly care in an infrastructure program. Others ridiculed it as a gift to the Service Employees International Union, which aims to organize caregivers. It was also blamed for omitting childcare.

For Ai-jen Poo, co-director of Caring Across Generations, a coalition of stakeholders working to strengthen the long-term care system, this was an answer to years of hard work.

“Although I’ve been fighting for it for years,” she said, “if you’d told me 10 years ago that the President of the United States would give a speech in which $ 400 billion would be allocated to improve access to these services and to strengthen this work. ” Kraft, I didn’t think it would happen. “

What has failed the debate on the President’s proposal is that, despite the large number, its ambitions remain uniquely narrow compared to the enormous and growing demands of an aging population.

Mr Biden’s proposal, which is part of his US $ 2 trillion employment plan, is only aimed at empowering Medicaid, which pays just over half the cost of long-term care in the country. And it is aimed only at home care and outpatient care in facilities such as day care centers for adults – not at nursing homes, which make up just over 40 percent of the Medicaid care budget.

Even so, the money would be used up very quickly.

Consider an important goal: increasing caregiver wages. In 2019, the typical wage for the 3.5 million household and personal care workers was $ 12.15 an hour. They earn less as janitors and telemarketers, less as workers in food processing plants or on farms. Many – usually women of color, often immigrants – live in poverty.

The helpers are employed by care facilities that bill Medicaid for their hours worked in the beneficiaries’ homes. The agencies regularly report labor shortages, which may not be surprising given the low pay.

Increasing wages can be essential to meet booming demand. The Department of Labor estimates that these occupations will require 1.6 million additional workers over 10 years.

It won’t be cheap, however. An increase in the hourly wages of the aides to $ 20 – still below the average wage in the country – would more than consume the eight-year effort of $ 400 billion. That would leave little money for other priorities, such as meeting the demand for care – 820,000 people were on the states’ waiting lists in 2018 with an average waiting time of more than three years – or the provision of more comprehensive services.

The battle for resources is likely to strain the coalition of unions and groups that advance the interests of elderly and disabled Americans who have worked together to advocate Mr. Biden’s plan. Even before nursing homes complain that they are being left out.

The president “needs to strike the right balance between reducing the waiting list and increasing wages,” said Paul Osterman, professor at the Massachusetts Institute of Technology’s Sloan School of Management who has written about the country’s care structures. “There is tension.”

Care for the elderly has long been at the center of political struggles over social security. President Lyndon B. Johnson considered bringing the benefits of establishing Medicare in the 1960s, said Howard Gleckman, an expert in long-term care at the Urban Institute. However, House Ways and Means Committee chair Wilbur Mills cautioned how expensive this approach would be when baby boomers retired. Better, he argued, make it part of Medicaid and let states shoulder a lot of the burden.

That compromise resulted in a patchwork of services that has abandoned millions of seniors and their families and yet consumes around a third of Medicaid spending – about $ 197 billion in 2018, according to the Kaiser Family Foundation. According to Kaiser’s calculations, Medicaid pays about half of the long-term care services. Payouts and private insurance together make up just over a quarter of the tab. (Other sources, like veteran programs, cover the rest.)

Unlike institutional care, which requires government Medicaid programs, home and community care services are optional. That explains the waiting lists. This also means that the quality of the services and the rules for using the services are very different.

Although the federal government pays at least half of the state’s Medicaid budgets, the states have plenty of leeway in how the program runs. In Pennsylvania, Medicaid pays an average of $ 50,300 per year per recipient of home or outpatient care. In New York it pays $ 65,600. In contrast, Medicaid pays $ 15,500 per recipient in Mississippi and $ 21,300 in Iowa.

This regulation has also left the middle class in the lurch. The private insurance market is shrinking and can no longer handle the high cost of end-of-life care: it’s too expensive for most Americans and too risky for most insurers.

As a result, middle-class Americans in need of long-term care either resort to relatives – usually daughters who throw millions of women out of work – or use up their resources until they qualify for Medicaid.

Regardless of the boundaries of the Biden proposal, proponents of its main constituencies – those in need of care and those who provide it – stand firm behind it. After all, this would be the largest expansion in long-term care support since the 1960s.

“The two big issues of waiting lists and labor are related,” said Nicole Jorwic, senior director of public policy at Arc, which promotes the interests of people with disabilities. “We are confident that we can do this in such a way that we can overcome the conflicts that have stopped progress in the past.”

And yet the dispute over resources could reopen the conflicts of the past. For example, when President Barack Obama proposed extending the Fair Labor Standards Act of 1938 to include domestic carers, who would cover them with minimum wage and overtime rules, attorneys for beneficiaries and their families opposed fearing that states with budgetary pressure would cut off -Service around 40 hours a week.

“We have a long way to go to get this into law and get it done,” said Haeyoung Yoon, senior policy director of the National Domestic Workers Alliance, of the Biden proposal. On the way, she said, the supporters have to stick together.

Given the scale of the need, some wonder if there could be a better approach to supporting long-term care than spending more money on Medicaid. The program is constantly being asked for resources that are forced to compete with education and other priorities in state budgets. And Republicans have repeatedly tried to narrow their scope.

“It’s hard to imagine that Medicaid is the right funding tool,” said Robert Espinoza, vice president of policy at PHI, a nonprofit research group that monitors the home care sector.

Some experts have instead proposed the creation of a new line of social insurance, possibly financed by payroll taxes, to provide a minimum of services to all.

A few years ago, the Long-Term Care Financing Collaborative, a group that was formed to ponder how to pay for long-term care for the elderly, reported that half of adults typically have “high levels of personal support at some point “Would need for two years at an average cost of $ 140,000. Today around six million people require these types of services, a number the group expects to grow to 16 million in less than 50 years.

In 2019, the National Social Insurance Academy published a report proposing nationwide insurance programs paid by a special tax to cover a range of services from early childhood care to family vacations to long-term care and support for older adults and the disabled.

This can be structured in a number of ways. One option for seniors, a disaster insurance plan that covers expenses up to $ 110 per day (in 2014, after a waiting period determined by the beneficiary’s income) could be funded by a one percentage point increase in Medicare tax.

Mr. Biden’s plan is not very detailed. Mr Gleckman of the Urban Institute notes that it has become vague since Mr Biden suggested it on the campaign – perhaps because he realized the tensions that would arise from it. In either case, a major overhaul of the system may be required.

“This is a significant historic investment,” said Espinoza. “But when you consider the extent of the crisis ahead of us, it is clear that this is only a first step.”

Categories
Health

5 issues to know earlier than the inventory market opens Thursday, April 15

5 things to know before the stock market opens Thursday, April 15

Here are the top news, trends, and analysis that investors need to get their trading day started:

1. Stocks are likely to burst on strong earnings reports

Traders on the floor of the New York Stock Exchange.

Source: NYSE

2. Covid Stimulus Checks Could Really Boost Retail Sales

People shop on 5th Avenue in New York during the coronavirus disease (COVID-19) pandemic on February 17, 2021.

Brendan McDermid | Reuters

The trading department reported Thursday that retail sales rose 9.8% in March, well above estimates for a 6.1% increase. A new series of Covid Stimulus Checks boosted consumer purchases last month as the U.S. economy continued to receive support from aggressive Congressional spending. Retail sales in February were revised up slightly, falling 2.7%.

The Department of Labor reported 576,000 initial jobless claims Thursday last week, well below expectations for 710,000 new registrations. This was certainly the lowest level since the pandemic began and was a sharp drop from the previous week’s revised upward of 769,000.

3. The BofA exceeds estimates for strong investment banking

Signage outside a Bank of America branch in San Francisco, California, the United States, on Thursday, Jan. 14, 2021.

David Paul Morris | Bloomberg | Getty Images

Bank of America’s profits exceeded estimates on strong investment banking and trading results and risk release releases as fewer consumers faced loan defaults. Like other banking competitors, BofA has benefited greatly from the improving US economic outlook in recent months.

Citigroup’s results exceeded analysts’ estimates for first quarter earnings with strong investment banking revenues and an above-expected loan loss provision release. The company also said it is closing retail banking operations in 13 countries in Asia and parts of Europe to focus more on wealth management outside of the US

4. Coinbase is set to jump after a strong but volatile debut

Monitors display Coinbase signage during the company’s IPO on April 14, 2021 on the Nasdaq marketplace in New York City.

Robert Nickelsberg | Getty Images

Coinbase Global shares rose another 8% on the Thursday before going public, a day after the cryptocurrency exchange debuted with a market value of nearly $ 86 billion. Nasdaq announced a reference price of $ 250 per share for Coinbase’s direct listing late Tuesday. In one volatile session, the stock opened at $ 381 and quickly rose to $ 429, for a market cap of $ 100 billion. It fell back below its debut price at one point, hitting a low of around $ 310. It closed at $ 328. Coinbase hit the public market when a record amount of cash was flowing into bitcoin and cryptocurrencies.

5. The CDC Panel is delaying the decision on J&J Covid’s vaccination break

Johnson & Johnson’s Janssen COVID-19 vaccine will be stored in Chicago, Illinois for use with United Airlines employees at the United Clinic at O’Hare International Airport on March 9, 2021.

Scott Olson | Getty Images

The CDC Advisory Committee on Immunization Practices has decided to postpone a decision on Johnson & Johnson’s Covid-19 vaccine while investigating cases of six women developing a rare but serious bleeding disorder, one person dead and one other is in critical condition. The panel met Wednesday, the day after the FDA called on states to temporarily stop using J & J’s vaccine “out of caution”. Moving the panel means the pause for J & J’s vaccine will continue to apply. The CDC committee unanimously voted for a reunion in a week.

– Follow all market action like a pro on CNBC Pro. Get the latest information on the pandemic on CNBC’s coronavirus blog.

Categories
Health

Western Warnings Tarnish Vaccines the World Badly Wants

Western Warnings Tarnish Vaccines the World Badly Needs

South Africa immediately copied the American break in Johnson & Johnson vaccinations and enraged doctors who still call for gunshots, especially in remote parts of the country. In February, health officials dropped the AstraZeneca vaccine there because of its limited effectiveness against a dangerous variant.

To date, only half of 1 percent of the population is vaccinated and only 10,000 shots are fired a day. At this rate, it could be weeks, if not longer, for a single rare case of blood clotting to occur, said Jeremy Nel, an infectious disease doctor in Johannesburg. He was dismayed by the decision to pause the shooting, given the risk of building confidence in vaccines in a country where two-fifths of the population say they don’t intend to vaccinate.

“The slower you go, the more that failure is measured in terms of death,” said Dr. Nel. “Even if you are late by a week, there is a non-trivial chance that will cost your life.”

The solution in many European countries – stop using apparently riskier vaccines in younger people who are less at risk of Covid-19 – would not be practical in Africa, where the average age in many countries is under 20.

Further restrictions would tighten the hurdles for Covax, including a lack of funding for any part of vaccination programs beyond doses at airports.

Mali, in West Africa, has administered 7 percent of the AstraZeneca doses administered by Covax. Sudan in East Africa has given 8 percent of the doses it has received.

Analysts fear that dissatisfaction with AstraZeneca and Johnson & Johnson vaccines could fuel demand for recordings made in Russia and China, which are far less well known. Some global health officials have turned their attention to the Novavax vaccine, which is not yet approved but makes up a third of the Covax portfolio.

Categories
Health

Over 200,00zero new coronavirus instances

Over 200,000 new coronavirus cases

A man is vaccinated at the Urban Primary Health Center in Uttar Pradesh, India.

Pradeep Gaur | SOPA pictures | LightRocket | Getty Images

India’s second wave of coronavirus infection is showing no signs of slowing.

The South Asian country reported more than 200,000 new cases and more than 1,000 deaths in a 24-hour period, according to the Ministry of Health. Most new infections are reported in a handful of states, including the western state of Maharashtra, which is home to India’s financial capital, Mumbai.

Government data also suggests that more states are seeing an upward trend in reported cases that have increased since February. The death rate is also rising as hospitals are under pressure, including the number of beds available. For example, a medical association in Gujarat state has reportedly asked the government to ensure 100% oxygen supply to hospitals treating Covid-19 patients.

India still has a relatively high rate of recovery.

Since the beginning of April, India has reported more than 1.9 million new cases and over 10,600 deaths, according to CNBC’s calculations of Health Department data. Between April 1 and April 7, India reported more than 652,000 cases. That number has almost doubled in the past eight days.

Earlier this week, India overtook Brazil to become the second worst infected country after the US just months after Prime Minister Narendra Modi reportedly declared victory over Covid-19.

Maharashtra lockdown

On Wednesday evening, India’s richest state was suspended until May 1 to break the chain of transmission. Maharashtra is considered to be the epicenter of the second wave of infections in India.

The guidelines issued by the Prime Minister of Maharashtra said that only essential services – including public transportation and food – would be operational between 7:00 a.m. and 8:00 p.m. local time and people would not be allowed into public spaces without valid reason.

The central government has reportedly attributed the second wave to people’s lack of commitment to wearing masks and practicing safe distancing.

India’s vaccination campaign

Categories
Health

What the Coronavirus Variants Imply for Testing

What the Coronavirus Variants Mean for Testing

In January 2020, just a few weeks after the first Covid-19 cases appeared in China, the full genome of the new coronavirus was published online. Using this genomic sequence, the scientists developed a wide range of diagnostic tests for the virus.

But the virus has mutated since then. And with the development of the coronavirus, the test landscape has also evolved. The emergence of new variants has generated great interest in the development of tests for certain virus mutations and concerns about the accuracy of some existing tests.

“With this Covid diagnostic, we had a time crisis, we had to get something out of it,” said Lorraine Lillis, scientific program manager at PATH, a global non-profit health organization that has been tracking coronavirus tests. “It usually takes a long time to diagnose and we would normally challenge it with multiple variations.” She added, “And we do it, but we do it in real time.”

The Food and Drug Administration has warned that new mutations in the coronavirus could make some tests less effective. And last week, PATH launched two online dashboards to monitor how certain variants can affect the performance of existing diagnostic tests.

So far, scientists have agreed that there is no evidence that the known worrying variants will cause tests to fail completely. “The tests are working very, very well today,” said Mara Aspinall, an expert in biomedical diagnostics at Arizona State University.

But Manufacturers and regulators need to remain vigilant to keep up with an ever-changing virus, scientists say. When variants elude detection, it can be of concern not only to individual patients who may not receive the treatment they need, but also to public health.

If a test misses someone infected with a variant, that person may not realize that they need to be isolated. “And then that person must not be quarantined, circulated in the community and possibly passed this variant on to others,” said Gary Schoolnik, doctor and infectious disease expert at Stanford University and chief medical officer of Visby Medical, a diagnostics company that does a coronavirus test. “And so, if variants are missing, a diagnostic test can actually promote the spread of this variant.”

Molecular tests, such as the widely used polymerase chain reaction or PCR test, are used to detect specific sequences of the coronavirus genome. If mutations occur in these “target” sequences, the tests may no longer be able to detect the virus, leading to false negative results.

“You could get into a situation where you were unlucky when you decided to take your test and something came up that made your test less effective,” said Nathan Grubaugh, a virologist at Yale University.

The gene for the virus’s signature spike protein, known as the S gene, has been particularly susceptible to mutation, and tests targeting this gene may miss certain variants. For example, Thermo Fisher’s TaqPath test fails to detect the mutated S gene of the B.1.1.7 variant, which was first identified in the UK and is now rapidly spreading in the US.

However, the test is not only based on the S gene. It has three goals, yet it can still provide accurate results by detecting two more sections of the coronavirus genome.

Only 1.3 percent of molecular tests are based solely on an S-gene target. This is based on calculations made by Rachel West, a postdoctoral fellow at the Johns Hopkins Center for Health Security. The rest either target more stable regions of the genome that are less likely to mutate, or have multiple target sequences, making them less prone to failure. “It is very unlikely that you will get mutations in all,” said Dr. Lillis.

Updated

April 14, 2021, 9:50 p.m. ET

The FDA has listed four different molecular tests “the performance of which could be affected by the variants,” but states that the tests should continue to work. Three of the tests have multiple objectives; A fourth can be a little less sensitive if the virus has a particular mutation and is present in very small amounts. (The four tests are the TaqPath Covid-19 Combo Kit, the Linea Covid-19 Assay Kit, the Xpert Xpress and Xpert Omni SARS-CoV-2, and the Accula SARS-CoV-2 test.)

“We don’t think these four tests are significantly affected,” said Dr. Tim Stenzel, who heads the FDA’s In Vitro Diagnostic and Radiological Health Office. “We published this information out of caution and transparency.”

Antigen tests are less sensitive than molecular tests, but they are usually cheaper and faster and are widely used in coronavirus screening programs. These tests detect specific proteins on the outside of the virus. Some genetic mutations could alter the structure of these proteins and allow them to evade detection.

Most antigen tests target the nucleocapsid protein. The gene that codes for this protein, known as the N gene, is more stable and mutated than the S gene, and the FDA has not listed any antigen tests as of concern. “We didn’t find any that hoisted a red flag, nor have we received any reports,” said Dr. Stenzel.

However, experts note that not every test maker discloses the specific sequences their tests target and the virus continues to mutate. “There is no evidence that any particular molecular assay, or even an antigen test, completely misses the boat for detection.” said Neha Agarwal, the assistant director of diagnostics at PATH. “But things will change.”

The FDA continues to monitor the situation and weekly reviews the coronavirus sequence databases to see if the virus is developing in a way that may help avoid diagnostic tests. “We are very vigilant,” said Dr. Stenzel. “And we will stay vigilant.”

As the variants spread, researchers are also working to develop and improve tests to detect them. At the moment, identifying a variant is typically a two-step process. First, a standard coronavirus test, such as a PCR test, is used to determine if the virus is present. If the test is positive, a sample will be sent for genomic sequencing.

“These two tasks are currently performed in two separate workflows,” said Juan Carlos Izpisua Belmonte, developmental biologist at the Salk Institute in La Jolla, California. “This means more time, work and resources.”

Many researchers are currently working on integrated solutions – tests that can be used to determine if someone is infected with the virus and whether they may have a particular variant.

For example, Dr. Izpisua Belmonte and colleague Mo Li, a stem cell biologist at King Abdullah University of Science and Technology in Saudi Arabia, described a new test method that can be identified in a recent article Mutations in up to five different regions of the coronavirus genome.

And Dr. Grubaugh and his colleagues have developed a PCR test that can be used to detect certain combinations of mutations that characterize three questionable variants: B.1.1.7; B.1,351, which was first discovered in South Africa; and P.1, first found in Brazil. (The work has not yet been published in a scientific journal.)

Dr. Grubaugh said researchers in Brazil, South Africa and elsewhere are already using the tests to sift through a mountain of coronavirus samples and identify those that should be prioritized for full genomic sequencing. “The main interest of our group is to improve genomic surveillance through sequencing, especially in areas with limited resources,” said Dr. Grubaugh. “If you want to know if there are variants, you need a way of triage.”

A number of companies are also starting to publish coronavirus tests that they say can differentiate between certain variants, although these are for research purposes only. It is “infinitely more difficult” to create a test that can definitely diagnose someone with a particular variant, said Dr. Grubaugh.

Similar mutations come in different variants, making it difficult to differentiate between them. The mutations of interest change with the virus, and sequencing remains the best way to get a complete picture of the virus.

But tests that can look for specific mutations could be an important public health tool, Ms. Agarwal said: “These newer diagnoses that examine the variants will be really crucial to understanding the epidemiology of the virus and I think our next generation plan the efforts against it. “

Categories
Health

Consultants talk about if it is attainable to succeed in Covid immunity

Experts discuss if it's possible to reach Covid immunity

People hold hands on Fifth Avenue amid the coronavirus pandemic on April 10, 2021 in New York City.

Noam Galai | Getty Images Entertainment | Getty Images

As Covid vaccines roll out around the world, many look forward to “herd immunity” – when the disease stops spreading quickly because the majority of the population is immune from vaccination or infection.

It is seen as a path to normalcy and something doctors and political leaders often discuss when talking about defeating Covid-19.

While there have been doubts as to whether herd immunity is possible, medical experts who have spoken to CNBC say it can be achieved. However, they point to a difficult path, as maintaining high levels of immunity will be a challenge.

“I think every part of the world will sooner or later reach herd immunity,” said Benjamin Cowling, director of the epidemiology and biostatistics department at the University of Hong Kong’s School of Public Health. Different communities could get there through vaccinations, infection, or a combination of both, he added.

Not everyone agrees.

An article last month in Nature identified five reasons herd immunity might not be possible. According to the report, the barriers to herd immunity include: new varieties, dwindling immunity, and questions about whether vaccines actually prevent transmission.

Shweta Bansal, a math biologist, told the publication, “Herd immunity is only relevant if we have a vaccine that blocks transmission. If we don’t, the only way to get herd immunity in the population is by to give everyone the vaccine. “”

Herd immunity: “Complicated” but possible

Health experts who spoke to CNBC have recognized that the factors raised in the article on nature could hinder progress toward herd immunity – but they believe that is still within reach.

“We’re not trying to eradicate it, we’re trying to stop the runaway community transmission. In that sense, we can achieve (herd immunity),” said Dale Fisher, professor of infectious diseases at the National University of Singapore’s Yong Loo Lin School of Medicine.

Dr. Anthony Fauci, chief medical officer to President Joe Biden, said 75% to 85% of people need to be vaccinated to create an “umbrella” of immunity that will prevent the virus from spreading. Fisher estimates the number is around 70%.

“Reaching 70% is possible, but there are many threats,” he said, explaining that the percentage of a population immune to Covid-19 would decrease as immunity wears off. make the vaccines less effective.

“Herd immunity is something very nice and conceptual, but it’s more complicated,” he said during a call. “If you want to call a magic number around 70% then all I am saying is very hard to come by and maintain.”

Herd immunity may not be permanent, but rather short-term.

Benjamin Cowling

School of Public Health at the University of Hong Kong

Cowling agreed that there is “no guarantee” that immunity levels would remain high over the long term. “Herd immunity may not be permanent, but rather short-term,” he said.

Still, it’s something the world can work towards, he added, emphasizing that refresher shots can help when protection is lost.

Back to the “normal”

It could take three to five years for the world to return to “completely normal,” said Carlos del Rio, a professor of medicine at Emory University School of Medicine.

“There are still a lot of broadcasts around the world and I think it will be some time before that changes,” he told CNBC’s Street Signs Asia on Monday.

The World Health Organization warned this week that the pandemic is “growing exponentially” and more than 4.4 million new Covid-19 cases have been reported in the past week.

The agency’s technical director for Covid-19, Maria Van Kerkhove, said the world has reached “a critical point in the pandemic”.

“Vaccines and vaccinations are going online, but they are not yet available in all parts of the world,” she added.

Fisher said the world is still “very susceptible to large outbreaks” – but cases could sporadic in five or ten years. In the meantime there will be a transition period.

“Herd immunity is not a binary phenomenon,” he said. “Most people think you either have it or you don’t – but it’s obviously gray in between.”

Cowling said he thinks the greatest risk for Covid will be in the next 12 months, but the threat will decrease afterwards as vaccines are introduced.

“What I would expect in the years to come is that the virus will still circulate, it will be endemic, but it will no longer be a major threat to public health,” he said.

– CNBC’s Berkeley Lovelace contributed to this report.

Categories
Health

Denmark says it’s completely stopping use of the AstraZeneca vaccine.

Denmark says it’s permanently stopping use of the AstraZeneca vaccine.

Denmark became the first country on Wednesday to plan to permanently stop administration of the AstraZeneca vaccine a month after it stopped using it after reports that a small number of recipients had developed a rare but serious bleeding disorder.

The country’s health authority director-general Soeren Brostroem said Denmark could stop using the vaccine as the pandemic was under control and it could rely on two other vaccines from Pfizer and Moderna.

The Danish announcement is another setback for the AstraZeneca shot, which is easy to store and relatively cheap, and should serve as the basis for vaccination campaigns around the world.

The country initially stopped using the vaccine on March 11, along with Iceland and Norway. Several other European countries including France, Germany and Italy followed suit last month.

The European Union’s Medicines Agency, the European Medicines Agency, later recommended countries continue to use the vaccine, saying its benefits far outweighed the potential risks for most people.

Last week, the European regulator listed blood clots as a possible very rare side effect of the vaccine.

Several countries that suspended and resumed use of the vaccine have since announced that they will discontinue use in younger people. The UK, which has given around 20 million AstraZeneca doses, said it would offer alternative vaccines to people under 30.

“Based on the scientific evidence, our overall assessment is that there is a real risk of serious side effects associated with using AstraZeneca’s Covid-19 vaccine,” said Danish health official Dr. Brostroem in a statement. “We have therefore decided to remove the vaccine from our vaccination program.”

“If Denmark were in a completely different situation, for example in the midst of a violent third outbreak and a health system under pressure,” he added, “then I would not hesitate to use the vaccine, even if it were rare.” but serious complications related to its use. “

Danish health officials said they might reintroduce the AstraZeneca vaccine “if the situation changes”.

Public health officials have warned that stopping vaccine delivery like AstraZeneca or Johnson & Johnson could do more harm than good. They find that out of seven million people in the United States who were vaccinated with the Johnson & Johnson single-dose vaccine, six women had developed the rare blood clots – fewer than one in a million. It is not yet known if the vaccine had anything to do with the clots, but even if it does, the risk is lower than being struck by lightning in any given year (one in 500,000).

Denmark, with a population of 5.8 million, managed to contain the pandemic better than its neighbor Sweden or many other European countries. As of Wednesday, Denmark had recorded 2,447 deaths related to Covid.

Nearly a million people in the country have received at least a first dose of a vaccine, 77 percent of them from Pfizer, according to the Danish Serum Institute. Around 15 percent received an initial dose of the AstraZeneca vaccine before authorities stopped using it last month, and the remaining 8 percent received the Moderna vaccine.

The country’s health officials said people who received a first dose of the AstraZeneca vaccine will be offered a different vaccine for their second dose.

Jasmina Nielsen contributed to the reporting.